Global Neuroendocrine Tumor Treatment Market, By Drug (Everolimus, Sunitinib Malate, Lu-Dotate, Lanreotide, Octreotide), Indication (Gastrointestinal NET, Lung NET, Pancreatic NET), End User (Hospitals, Oncology Centers), and Geography - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025

Neuroendocrine Tumor Treatment

Incidence and prevalence of neuroendocrine tumor is steadily rising, mainly due Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2), Neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (VHL) and Tuberous sclerosis complex (TSC) disease in the U.S. Moreover, based on a study published in the JAMA Oncology Journal, survival rate for all neuroendocrine tumor treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumor treatment and pancreatic neuroendocrine tumor treatment. This is mainly attributed to improved outcomes of availability of better therapies and early diagnosis. Introduction of new therapies and extended indications for approved drugs would benefit the growth of neuroendocrine tumor treatment market in North America and in turn is expected to significantly fuel growth of the global market. U.S. is the largest market for NET, in terms of revenue. No specific data is available regarding incidence of neuroendocrine tumors in Canada. However, according to the Canadian Cancer Society, 315 people in Canada were diagnosed with endocrine cancers in 2012 and the rate is increasing with early diagnosis and stage migration.

North America neuroendocrine tumor treatment market is expected to dominate the global gastrointestinal NET segment throughout the forecast period. According to Coherent Market Insights analysis, various national universities and small scale pharma-company work on developing various NET drugs and modify clinical approach to treat neuroendocrine tumors. This gives pharma and biotech companies a major opportunity to market their products in the U.S.

The global neuroendocrine tumor treatment market was valued at US$ 1,197.3 million in 2015 and is expected to witness a CAGR of 10.5% during the forecast period (2017 – 2025)

Figure 1. Global Neuroendocrine Tumor Treatment Market Share, By Drug (%)

neuroendocrine tumor treatment market

Source: Coherent Market Insights Analysis (2017)

Innovate drug in pharmaceutical company product pipeline to boost the Neuroendocrine Tumor Treatment Market

There are various medical treatment to treat cancer, and targeted therapy is one of the most preferred to treat neuroendocrine tumor treatment. Targeted therapy is a futuristic and highly effective approach for treating cancers and hence, targeted NET therapies are projected to gain significant demand in the near future. Though somatostatins are effective in treating some types of pituitary tumors, regulatory approval for NET is expected to further encourage its research as a combination therapy with targeted drugs. Pasireotide is another somatostatin analogue under study for treating NET. Somatostain analogs are the preferred therapy for chronic control and are effective for long-term management. Also, Avastin (Bevacizumab), a monoclonal antibody, is being studied for its efficacy in treating carcinoid tumors. Netazepide, gastrin/CCK2 receptor antagonist, is found to shrink tumors in patients having carcinoid tumors of the stomach and high gastrin levels. Being a rare disease, regulatory agencies are providing fast-track and orphan drug status to the potential drug candidates.

Imaging technique is one of the useful tool for assessing key tumor which in turn will boost growth of the neuroendocrine tumor treatment market

There are various other types of neuroendocrine tumors that may occur across various parts of the body and have different growth patterns. The other neuroendocrine tumors include thymus, thyroid gland, adrenal gland and pituitary gland. These neuroendocrine cells multiply at a very slow pace as compared to a regular neuroendocrine cells of GI, Lungs, and Pancreases. These seldom cause symptoms at an early diseases stage, however, when these symptoms are identified they are sometimes misdiagnosed as any other lump. It is highly important to identify the other neuroendocrine tumors, as if left undiagnosed, condition may lead to malignant tumor. Proper treatment planning is necessary as Neuroendocrine Tumor Treatment that can otherwise be contained in a particular area of the body, may spread to nearby tissues or lymph nodes and may eventually spread throughout the body. There are limited treatment options for pancreatic neuroendocrine tumors. One of the most significant and common treatment is surgical removal of tumors. Apart from surgical treatment, there are few treatments such as chemotherapy, targeted therapy, radiation therapy, etc. Currently, there is no standard treatment to treat pancreatic Neuroendocrine Tumor Treatment. However, two targeted therapy drugs namely, Afinitor and Sutent have received FDA-approval for treatment of advanced pancreatic neuroendocrine tumors and is beneficial for some patients according to the type and severity of the indication.  

However, increasing adoption of advanced diagnostic imaging techniques such as endoscopic ultrasonography would result in very small, clinically insignificant neuroendocrine tumors being discovered coincidentally. These being unrelated to symptoms, such neuroendocrine tumors may not require surgical excision, and hence would fuel growth of the neuroendocrine tumor treatment market.6

Neuroendocrine tumors (NETs) result from the abnormal growth of neoplasms that originate from cells of the various endocrine glands and nervous systems. Though most of these are benign, some tend to become malignant and may turn cancerous in the long term. Neuroendocrine tumors are generally infected firstly in intestine, which are often known as carcinoid tumors, pancreas is the second most prime organ in the body where the growth of NET is common.

The neuroendocrine tumor treatment market is expected to gain steady traction in the foreseeable future as there are many products in various pharmaceutical company product pipeline. As there is an increase in NET incidence in various geographies, there is a need for fast tract drug approval process which will bring the products in market in a very short time.

Market Dynamics

The growing incidence of GI and Lung Neuroendocrine Tumors is a key factor fueling growth of the global neuroendocrine tumor treatment market. According to a research study published by Novartis in 2015, GI Neuroendocrine comprises 61% Neuroendocrine Tumors (NET) diagnosis and 5%-44% of GI NET have advanced disease at time of diagnosis, with survival rate drastically decreasing according to severity. The 5-year survival for NET of the small intestine was 86.2%, 82.7% for stomach and 67.4% for colon. Apart from GI and Lung Neuroendocrine, there are other factors which influence the NET are hormonal imbalance at pituitary gland and thyroid gland. Rising demand for various imagining technique in North America and Europe are factors projected to fuel growth of the global market over the forecast period. Drug portfolio expansion and development of new products that can inhibit the excess hormone production, are some of the other factors augmenting growth of the global neuroendocrine tumor treatment market.

Market Taxonomy

This report segments the global neuroendocrine tumor treatment market on the basis of drug, indication, end user, and geography. On the basis of drug, the neuroendocrine tumor treatment market is categorized into Everolimus, Sunitinib Malate, Lu-Dotate, Lanreotide, and Octreotide. On the basis of indication, the neuroendocrine tumor treatment market is categorized into Gastrointestinal Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor and Others Neuroendocrine Tumor. On the basis of end-user, the neuroendocrine tumor treatment market is categorized into hospital, oncology centers, and others which includes GI centers, Cardio-thoracic centers, NET centers. For comprehensive understanding of market dynamics, the global neuroendocrine tumor treatment market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key features of the study:

  • This report provides in-depth analysis of the neuroendocrine tumor treatment and is its effects, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2025, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global neuroendocrine tumor treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc.and Exelixis, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
  • The global neuroendocrine tumor treatment market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for neuroendocrine tumor treatment market, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the neuroendocrine tumor treatment market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Neuroendocrine Tumor Treatment Market, By Drug:
    • Everolimus
    • Sunitinib Malate
    • Lu-Dotate
    • Lanreotide
    • Octreotide
  • Global Neuroendocrine Tumor Treatment Market, By Indication:
    • Gastrointestinal NET
    • Lung NET
    • Pancreatic NET
    • Others NET
  • Global Neuroendocrine Tumor Treatment Market, By End User:
    • Hospitals
    • Oncology Centers
    • Others
  • Global Neuroendocrine Tumor Treatment Market, By Geography:
    • North America
      • U.S.
        • U.S. Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • U.S. Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • U.S. Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Canada
        • Canada Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Canada Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Canada Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
    • Europe
      • U.K.
        • U.K. Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • U.K. Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • U.K. Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Germany
        • Germany Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Germany Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Germany Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Italy
        • Italy Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Italy Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Italy Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • France
        • France Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • France Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • France Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Spain
        • Spain Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Spain Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Spain Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Russia
        • Russia Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Russia Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Russia Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Rest of Europe
        • Rest of Europe Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Rest of Europe Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Rest of Europe Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
    • Asia-Pacific
      • China
        • China Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • China Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • China Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • India
        • India Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • India Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • India Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Japan
        • Japan Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Japan Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Japan Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • ASEAN
        • ASEAN Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • ASEAN Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • ASEAN Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Australia
        • Australia Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Australia Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Australia Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • South Korea
        • South Korea Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • South Korea Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • South Korea Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Rest of Asia Pacific
        • Rest of Asia Pacific Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Rest of Asia Pacific Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Rest of Asia Pacific Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
    • Latin America
      • Brazil
        • Brazil Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Brazil Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Brazil Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Mexico
        • Mexico Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Mexico Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Mexico Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Rest of Latin America
        • Rest of Latin America Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Rest of Latin America Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Rest of Latin America Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
          •  
    • Middle East
      • GCC
        • GCC Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • GCC Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • GCC Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Israel
        • Israel Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Israel Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Israel Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Rest of Middle East
        • Rest of Middle East Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Rest of Middle East Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Rest of Middle East Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
    • Africa
      • North Africa
        • North Africa Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • North Africa Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • North Africa Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • Central Africa
        • Central Africa Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • Central Africa Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • Central Africa Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
      • South Africa
        • South Africa Neuroendocrine Tumor Treatment Market, By Drug:
          • Everolimus
          • Sunitinib Malate
          • Lu-Dotate
          • Lanreotide
          • Octreotide
        • South Africa Neuroendocrine Tumor Treatment Market, By Indication:
          • Gastrointestinal NET
          • Lung NET
          • Pancreatic NET
          • Others NET
        • South Africa Neuroendocrine Tumor Treatment Market, By End User:
          • Hospitals
          • Oncology Centers
          • Others
  • Company Profiles
    • Pfizer Inc*
      • Company Overview
      • Drug Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Novartis AG
    • Ispen
    • Advanced Accelerator Applications
    • Tarveda Therapeutics
    • Progenics Pharmaceuticals, Inc.
    • Hutchison Medipharma Limited
    • Dauntless Pharmaceuticals Inc.
    • Exelixis, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet By Drug
      • Market Snippet By Indication
      • Market Snippet By End User
      • Market Snippet By Geography
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
        • Supply Side Drivers
        • Demand Side Drivers
        • Economic Drivers
      • Restraints
      • Market Opportunities
    • Global NET Survey
    • Mergers and Acquisitions
    • Marketing Strategies – Novartis, Ipsen, Pfizer
    • Product Pipeline
  4. Global Neuroendocrine Tumor Treatment Market, By Drugs, 2016 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, 2016 - 2025
      • Segment Trends
    • Everolimus
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
    • Sunitinib Malate
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
    • Lu-Dotate
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
    • Lanreotide
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
    • Octreotide
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
  5. Global Neuroendocrine Tumor Treatment Market, By Indication, 2016 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, 2016 - 2025
      • Segment Trends
    • Gastrointestinal NET
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
    • Lung NET
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
    • Pancreatic NET
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
    • Others NET
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
      •  
  6. Global Neuroendocrine Tumor Treatment Market, By End User, 2016 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, 2016 - 2025
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
    • Oncology Centers
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
    • Others (GI centers, Cardiothoracic centers, NET centers, etc.)Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
  7. Global Neuroendocrine Tumor Treatment Market, By Geography, 2016 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, For Regions, 2016 - 2025
    • North America
      • Market Share Analysis, By Country, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2025
        • U.S.
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Canada
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
    • Europe
      • Market Share Analysis, By Country, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2025
        • U.K.
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Germany
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Italy
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • France
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Spain
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Russia
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Rest of Europe
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
    • Asia Pacific
      • Market Share Analysis, By Country, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2025
        • China
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • India
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Japan
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • ASEAN
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Australia
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • South Korea
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Rest of Asia Pacific
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
    • Latin America
      • Market Share Analysis, By Country, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2025
        • Brazil
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Mexico
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Argentina
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Rest of Latin America
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
    • Middle East
      • Market Share Analysis, By Country, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2025
        • GCC Countries
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Israel
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Rest of Middle East
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
    • Africa
      • Market Share Analysis, By Country, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2025
        • Northern Africa
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • Central Africa
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
        • South Africa
          • Country Trends
          • Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
          • Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Ipsen
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Advanced Accelerator Applications
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Tarveda Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Progenics Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Hutchison Medipharma Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Dauntless Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Exelixis, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 20 market data tables and 30 figures on "Neuroendocrine Tumor Treatment Market - Global forecast to 2025”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.